ULISSE BIOMED SPA (UBM.MI) Stock Price & Overview
BIT:UBM • IT0005451213
Current stock price
The current stock price of UBM.MI is 0.8 EUR. Today UBM.MI is down by 0%. In the past month the price decreased by -24.88%. In the past year, price decreased by -68.19%.
UBM.MI Key Statistics
- Market Cap
- 20.408M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.20
- Dividend Yield
- N/A
UBM.MI Stock Performance
UBM.MI Stock Chart
UBM.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to UBM.MI. When comparing the yearly performance of all stocks, UBM.MI is a bad performer in the overall market: 95.32% of all stocks are doing better.
UBM.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UBM.MI. UBM.MI has a bad profitability rating. Also its financial health evaluation is rather negative.
UBM.MI Earnings
UBM.MI Forecast & Estimates
5 analysts have analysed UBM.MI and the average price target is 1.52 EUR. This implies a price increase of 89.98% is expected in the next year compared to the current price of 0.8.
For the next year, analysts expect an EPS growth of 84.6% and a revenue growth -19.59% for UBM.MI
UBM.MI Groups
Sector & Classification
UBM.MI Financial Highlights
Over the last trailing twelve months UBM.MI reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 65.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.16% | ||
| ROE | -24.96% | ||
| Debt/Equity | 0.05 |
UBM.MI Ownership
UBM.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.34 | 38.17B | ||
| 1AE | ARGENX SE | 25.37 | 38.17B | ||
| 22UA | BIONTECH SE-ADR | N/A | 19.092B | ||
| ABVX | ABIVAX SA | N/A | 8.477B | ||
| 2X1 | ABIVAX SA | N/A | 8.445B | ||
| GLPG | GALAPAGOS NV | N/A | 1.877B | ||
| GXE | GALAPAGOS NV | N/A | 1.877B | ||
| NANO | NANOBIOTIX | N/A | 1.42B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.071B | ||
| PHIL | PHILOGEN SPA | 18.17 | 657.9M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 862.75 | 429.025M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About UBM.MI
Company Profile
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine and currently employs 23 full-time employees. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Company Info
IPO: 2021-08-06
ULISSE BIOMED SPA
Via Aquileia 17
Udine UDINE IT
Employees: 22
Phone: 390403757540
ULISSE BIOMED SPA / UBM.MI FAQ
Can you describe the business of ULISSE BIOMED SPA?
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine and currently employs 23 full-time employees. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Can you provide the latest stock price for ULISSE BIOMED SPA?
The current stock price of UBM.MI is 0.8 EUR.
Does UBM stock pay dividends?
UBM.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of UBM stock?
UBM.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ULISSE BIOMED SPA belong to?
ULISSE BIOMED SPA (UBM.MI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for UBM stock?
You can find the ownership structure of ULISSE BIOMED SPA (UBM.MI) on the Ownership tab.